Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy

Trial Profile

Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2017

At a glance

  • Drugs Rifaximin (Primary) ; Lactulose
  • Indications Hepatic encephalopathy; Liver failure
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 05 Jan 2016 Planned End Date changed from 1 Oct 2016 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
    • 05 Jan 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Jan 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top